Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 4 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neurofibromatosis 2 1

Interventions

pembrolizumab 1023 Carboplatin 964 Paclitaxel 933 Gemcitabine 794 Cisplatin 751 Docetaxel 683 Bevacizumab 609 Pemetrexed 502 Nivolumab 487 Cyclophosphamide 471 Capecitabine 461 Fluorouracil 418 Dexamethasone 403 Rituximab 372 Oxaliplatin 348 Injections 345 atezolizumab 298 Trastuzumab 298 Leucovorin 288 Cetuximab 282 Irinotecan 268 130-nm albumin-bound paclitaxel 254 Prednisone 245 Doxorubicin 240 Ipilimumab 226 Lenalidomide 220 fludarabine 218 Fulvestrant 217 durvalumab 205 Erlotinib Hydrochloride 188

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Interventional × HDAC-42 × Clear all

NCT05130866 2025-10-07

POPLAR-NF2

Recursion Pharmaceuticals Inc.

Phase 2/3 Terminated

Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡